Aminoalkylindole
From Wikipedia, the free encyclopedia
Aminoalkylindoles (AAIs) are a family of cannabinergic compound that act as a cannabinoid receptor agonist. They were invented by pharmaceutical company Sterling-Winthrop in the early 1990s as potential non-steroidal anti-inflammatory agents.[1]
Legality[edit]
 |
This section needs to be updated. (November 2013) |
Aminoalkylindole are now commonly found in synthetic cannabis designer drugs.[2]
In the United States, the DEA added the aminoalkylindole JWH-200 to Schedule I of the Controlled Substances Act on 1 March 2011 for 12 months.[2][3]
References[edit]
- ^ Emmanuel S. Onaivi (2006). Marijuana and Cannabinoid Research: Methods and Protocols. Springer. pp. 128–. ISBN 978-1-59259-999-8.
- ^ a b "Synthetic Cannabinoids". American Association for Clinical Chemistry. 2013-02-01. Retrieved 2013-11-17.
- ^ "Schedules of Controlled Substances: Temporary Placement of Five Synthetic Cannabinoids Into Schedule I". Federal Register. 2011-03-01. Retrieved 2013-11-17.
